Together, our findings suggest that a circulating protein, sST2, in the brain milieu plays a key role in APOE-ε4-dependent AD pathogenesis in females—by modulating the activation and Aβ-clearance capacity of microglia—and therefore might be a novel target for AD therapy. The gene discussed is APOE; the disease is Alzheimer disease.